Osimertinib: all 176 studies that test it
Page 2 of 2. Open to participants first (45), then studies with results posted, then the rest; newest registration first within each.
- Roll Over StudY for Patients Who Have Completed a Previous Oncology Study With Osimertinib (TAGRISSO) (ROSY-T)Active, not recruitingNCT05629234Phase 3
- Study to Assess the Efficacy and Safety of Adjuvant Osimertinib in NSCLC With Uncommon EGFRmActive, not recruitingNCT05546866Phase 2
- A Study of 5 Years of Adjuvant Osimertinib in Completely Resected Epidermal Growth Factor Receptor Mutation (EGFRm) Non-small Cell Lung Carcinoma (NSCLC)Active, not recruitingNCT05526755Phase 2
- Study of Osimertinib+Bevacizumab+Chemotherapy for EGFR+ Advanced Non-Small Cell Lung Cancer With Concurrent MutationsStatus unknownNCT05507606Phase 2
- Correlation Between Efficacy of Osimertinib and EGFR T790M Status and Ratio Via ddPCR in NSCLCStatus unknownNCT05458726Phase 2
- Combining Afatinib and Concurrent Chemotherapy, Followed by Osimertinib and Concurrent Chemotherapy, in Untreated EGFR Positive NSCLC TumorsCompletedNCT05298176Phase 2
- TQ-B3525 Tablets Combined With Osimertinib Mesylate Tablets in the Treatment of Advanced Non-Small Cell Lung CancerStatus unknownNCT05284994Phase 1/2
- Savolitinib Plus Osimertinib Versus Platinum-based Doublet Chemotherapy in Participants With Non-Small Cell Lung Cancer Who Have Progressed on Osimertinib TreatmentActive, not recruitingNCT05261399Phase 3
- Minnelide and Osimertinib for the Treatment of Advanced EGFR Mutated Non-Small Cell Lung CancerActive, not recruitingNCT05166616Phase 1
- Efficacy and Safety of JMT101 Combined With Osimertinib in Patients With Non-Small Cell Lung CancerStatus unknownNCT05132777Phase 2
- A Phase 1a/1b Study to Determine the Recommended Phase 2 Dose, of Tepotinib in Participants With MET Alterations and Brain TumorsWithdrawnNCT05120960Phase 1
- A Global Study to Assess the Effects of Osimertinib in Participants With EGFRm Stage IA2-IA3 NSCLC Following Complete Tumour ResectionActive, not recruitingNCT05120349Phase 3
- Radiation During Osimertinib Treatment: a Safety and Efficacy Cohort StudyActive, not recruitingNCT05089916Phase 2
- Salvage Surgery Following Downstaging of Advanced Non-small Cell Lung Cancer by Targeted Therapy (SDANT)Status unknownNCT05085054Phase 2
- SI-B001 Combined With Osimertinib Mesylate Tablets in the Treatment of Recurrent Metastatic Non-small Cell Lung Cancer.Active, not recruitingNCT05020769Phase 2/3
- Aurora Kinase Inhibitor LY3295668 in Combination With Osimertinib for the Treatment of Advanced or Metastatic EGFR-Mutant Non-squamous Non-small Cell Lung CancerCompletedNCT05017025Phase 1/2
- Study on Savolitinib Combined With Osimertinib in Treatment of Advanced NSCLC With MET AmplificationCompletedNCT05015608Phase 3
- Osimertinib Combined With Bevacizumab in the Treatment Epidermal Growth Factor Receptor (EGFR) Exon 20 Insertions Metastatic Non-Small Cell Lung CancerStatus unknownNCT04974879Phase 2
- A Study of Anti-Cancer Therapies Targeting the MAPK Pathway in Patients With Advanced NSCLCCompletedNCT04959981Phase 1
- Osimertinib and Locally Ablative Radiotherapy in Patients With Synchronous Oligo-metastatic EGFR Mutant NSCLC (STEREO)TerminatedNCT04908956Phase 2
- (SYMPHONY) Phase 1/2 Study Targeting EGFR Resistance Mechanisms in NSCLCTerminatedNCT04862780Phase 1
- Best EGFR-TKI Sequence in NSCLC Harboring EGFR MutationsStatus unknownNCT04811001Phase 2
- Advanced Lung Tumor Treated by Osimertinib Plus AnlotinibCompletedNCT04770688Phase 1/2
- SRT for Residual Oligometastases of NSCLC After 3rd Generation EGFR-TKIsCompletedNCT04764214Phase 2
- Safety and Efficacy of Combining APL-101 With Frontline Osimertinib in Patients With EGFR-mutated Metastatic Non-small Cell Lung Cancer (NSCLC)Active, not recruitingNCT04743505Phase 1/2
- Study of Intravenous (IV) ABBV-637 Alone or in Combination With IV Docetaxel/Osimertinib to Assess Adverse Events and Change in Disease Activity in Adult Participants With Relapsed/Refractory (R/R) Solid TumorsActive, not recruitingNCT04721015Phase 1
- HER3-DXd (Patritumab Deruxtecan; U3-1402) in Combination With Osimertinib in Subjects With Locally Advanced or Metastatic EGFR-mutated Non-Small Cell Lung CancerActive, not recruitingNCT04676477Phase 1
- Efficacy and Safety of 80mg Osimertinib in Patients With Non-small Cell Lung Cancer(NSCLC)CompletedNCT04563871Phase 2
- Osimertinib and Abemaciclib in EGFR Mutant Non-Small Cell Lung Cancer After Osimertinib ResistanceActive, not recruitingNCT04545710Phase 2
- Temodar Plus Tyrosine Kinase Inhibitors for Progressive CNS DiseaseCompletedNCT04541407Phase 1
- Osimertinib Combined With Anlotinib in EGFR T790M Mutated NSCLC Patients With Progression on Osimertinib TreatmentTerminatedNCT04438902Phase 2
- Osimertinib With Bevacizumab for Leptomeningeal Metastasis From EGFR-mutation Non-Small Cell Lung CancerStatus unknownNCT04425681Phase 2
- Necitumumab and Trastuzumab in Combination With Osimertinib for the Treatment of Refractory Epidermal Growth Factor Receptor (EGFR)-Mutated Stage IV Non-small Cell Lung CancerActive, not recruitingNCT04285671Phase 1/2
- Study of Osimertinib in Patients with a Lung Cancer with Brain or Leptomeningeal Metastases with EGFR MutationCompletedNCT04233021Phase 2
- Safety and Efficacy of Combination Osimertinib and Ipilimumab in Patients w EGFR Mutated NSCLCActive, not recruitingNCT04141644Phase 1
- Alisertib in Combination With Osimertinib in Metastatic EGFR-mutant Lung CancerCompletedNCT04085315Phase 1
- A Study of APG-1252 Plus Osimertinib(AZD9291) in EGFR TKI Resistant NSCLC PatientsActive, not recruitingNCT04001777Phase 1
- Whole Genomic Landscape of Advanced EGFR-mutant NSCLCActive, not recruitingNCT03969823Not applicable
- Phase 2 Platform Study in Patients With Advanced Non-Small Lung Cancer Who Progressed on First-Line Osimertinib Therapy (ORCHARD)Active, not recruitingNCT03944772Phase 2
- Niraparib in Combination With Osimertinib in EGFR-Mutated Advanced Lung CancerTerminatedNCT03891615Phase 1
- MEchanisms of Resistance in EGFR Mutated Nonpretreated Advanced Lung Cancer Receiving OSimErtibActive, not recruitingNCT03865511Phase 2
- Study of Dacomitinib and Osimertinib for Patients With Advanced EGFR Mutant Lung CancerCompletedNCT03810807Phase 1
- Exploring the Theragnostic Value of Osimertinib in EGFR-mutated Lung Cancer (THEROS)CompletedNCT03810066Phase 2
- First-line Treatment With Osimertinib in EGFR-mutated Non-small Cell Lung CancerActive, not recruitingNCT03804580Phase 2
- T-DM1 and Osimertinib Combination Treatment to Target HER2 Bypass Track Resistance in EGFR Mutation Positive NSCLCTerminatedNCT03784599Phase 2
- A Pilot Study of Dacomitinib With or Without Osimertinib for Patients With Metastatic EGFR Mutant Lung Cancers With Disease Progression on Osimertinib.CompletedNCT03755102Early Phase 1
- 18F-FDG PET and Osimertinib in Evaluating Glucose Utilization in Patients with EGFR Activated Recurrent GlioblastomaCompletedNCT03732352Phase 2
- Study of Osimertinib and Stereotactic Ablative Radiation (SABR) in EGFR Mutant NSCLCActive, not recruitingNCT03667820Phase 2
- Osimertinib In EGFR Mutant Lung CancerActive, not recruitingNCT03586453Phase 2
- A Study of the Combination of Osimertinib, Platinum and Etoposide for Patients With Metastatic EGFR Mutant Lung CancersActive, not recruitingNCT03567642Phase 1
- Osimertinib With Stereotactic Radiosurgery (SRS) in Brain Metastases From EGFR Positive NSCLCCompletedNCT03535363Phase 1
- Osimertinib as First-line Therapy for Patients With Late-stage Lung CancerStatus unknownNCT03460275Phase 2
- Uncommon EGFR AZD9291Status unknownNCT03424759Phase 2
- TAGRISSO (Osimertinib) in NSCLC Patients in Whom T790 Mutations Are Detected by Liquid BiopsyCompletedNCT03394118Phase 2
- A Phase 2 Study of Osimertinib in Combination With Selumetinib in EGFR Inhibitor naïve Advanced EGFR Mutant Lung CancerActive, not recruitingNCT03392246Phase 2
- Study of AZD9291 in NSCLC Patients Harboring T790M Mutation Who Failed EGFR TKI and With Brain and/or LMSStatus unknownNCT03257124Phase 2
- Osimertinib and Gefitinib in EGFR Inhibitor naïve Advanced EGFR Mutant Lung CancerActive, not recruitingNCT03122717Phase 1/2
- Open Label, Prospective Study to Investigate Efficacy and Safety of AZD9291 in BM From NSCLC Patients With EGFR T790MStatus unknownNCT02972333Phase 3
- Osimertinib or Docetaxel-bevacizumab as Third-line Treatment in EGFR T790M Mutated Non-Small Cell Lung CancerCompletedNCT02959749Phase 2/3
- Study to Assess Osimertinib in Patients w/ Adv Solid Tumours & Normal Kidney Function or Severe Kidney ImpairmentCompletedNCT02923947Phase 1
- An Open-Label Phase 1/2 Study of Itacitinib in Combination With Osimertinib in Subjects With Non-Small Cell Lung CancerCompletedNCT02917993Phase 1/2
- Study to Assess the Effect of Osimertinib (TAGRISSO™ ) on Blood Levels of Fexofenadine in Patients With EGFRm+ NSCLCCompletedNCT02908750Phase 1
- Neo-adjuvant Trial With AZD9291 in EGFRm+ Stage IIIA/B NSCLCStatus unknownNCT02824952Phase 2
- Phase II Study of AZD9291 in Advanced Stage NSCLC With EGFR and T790M Mutations Detected in Plasma Ct-DNAStatus unknownNCT02811354Phase 2
- Liquid Biopsy as a Tool to Evaluate Resistance to First and Third (AZD9291) (EGFR) (TKIs) in (EGFR) Mutant NSCLCStatus unknownNCT02771314Phase 2
- Osimertinib in First and Second Line Treatment of NSCLC Harboring EGFR Mutations From Circulating Tumor DNACompletedNCT02769286Phase 2
- Intracranial Activity of AZD9291 (TAGRISSO) in Advanced EGFRm NSCLC Patients With Asymptomatic Brain MetastasesStatus unknownNCT02736513Phase 2
- National Lung Matrix Trial: Multi-drug Phase II Trial in Non-Small Cell Lung CancerCompletedNCT02664935Phase 2
- Osimertinib and Navitoclax in Treating Patients With EGFR-Positive Previously Treated Advanced or Metastatic Non-small Cell Lung CancerCompletedNCT02520778Phase 1
- AZD9291, an Irreversible EGFR-TKI, in Relapsed EGFR-mutated Non-small Cell Lung Cancer Patients Previously Treated With an EGFR-TKI, Coupled to Extensive Translational StudiesStatus unknownNCT02504346Phase 2
- Testing the Combination of MLN0128 (TAK-228) and AZD9291 in Advanced EGFR (Epidermal Growth Factor Receptor) Mutation Positive Non-small Cell Lung CancerActive, not recruitingNCT02503722Phase 1
- Osimertinib and Necitumumab in Treating Patients With EGFR-Mutant Stage IV or Recurrent Non-small Cell Lung Cancer Who Have Progressed on a Previous EGFR Tyrosine Kinase InhibitorActive, not recruitingNCT02496663Phase 1
- Targeted Therapy Directed by Genetic Testing in Treating Patients With Advanced Refractory Solid Tumors, Lymphomas, or Multiple Myeloma (The MATCH Screening Trial)Active, not recruitingNCT02465060Phase 2
- Oral Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors, AZD3759 or AZD9291, in Patients Who Have Advanced Non-Small Cell Lung CancerCompletedNCT02228369Phase 1
- Study to Assess the Blood Levels and Safety of AZD9291 in Patients With Advanced Solid Tumours and Normal Liver Function or Mild or Moderate Liver ImpairmentCompletedNCT02161770Phase 1
- To Determine the Relative Bioavailability of Different Formulations of AZD9291 and the Effect of Food.CompletedNCT01951599Phase 1